t.ibarra

TL2 Moderator · Izmir

Contributes reviews on supplier material. Based in Izmir.

Joined 30 November 2024 · last posted 4h

83Posts here

1Topics

0Solutions

195Likes received

136Likes given

18Badges

108Days visited

759Posts read

Recent activity

Full stream

What a reversed-phase purity number actually is Replied, post #102 · Analytics › HPLC & UHPLC · 28 Jul 2026 · 0 likes I read post #100 twice before replying, because I had assumed the opposite. System suitability testing: injections run before and during the sample run to establish…
Micro-titration: a disputed topic, argued properly Replied, post #110 · Practice › Dosing & titration · 24 Jul 2026 · 0 likes Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a…
Prior authorisation: what the criteria usually require — a second dataset Replied, post #52 · Access › Insurance & coverage · 21 Jul 2026 · 4 likes Out-of-pocket costs: if insurance is not covering it, asking about patient assistance programmes run by manufacturers can reduce costs. Eligibility requirements exist…
Solubility limits and what a cloudy solution is telling you Replied, post #15 · Pharmacology › Formulation chemistry · 16 Jul 2026 · 0 likes This follows post #12 rather than contradicting it. Antioxidants: compounds that prevent oxidation (which damages peptides) are sometimes included. Methionine oxidation…
Primary endpoint hierarchies and why order matters — one year on Replied, post #47 · Evidence › Trials · 15 Jul 2026 · 0 likes Intent-to-treat versus per-protocol: ITT includes everyone assigned regardless of whether they took the drug. Per-protocol includes only those who completed it as…
What I would want from a home test that does not exist yet — what changed since Replied, post #92 · Analytics › Home & field testing · 13 Jul 2026 · 10 likes What you can use home tests for: confirmation that a solution contains peptide (as opposed to being saline alone), rough screening for very different compounds…
Follow-up: How compounding permissions changed when supply normalised Replied, post #13 · Sourcing › Regulatory · 12 Jul 2026 · 0 likes Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a…
Pooling trials with different estimands Replied, post #37 · Evidence › Meta-analyses · 20 Jun 2026 · 7 likes On post #33 — agreed on the reasoning, with one qualification. Why forest plots are more informative than pooled numbers: they show the variation across studies, which…
I joined for one answer and stayed for a year — what changed my mind Replied, post #19 · Start Here › Welcome · 12 Jun 2026 · 3 likes Coming back to post #17, because the follow-up matters more than the original answer. Trust levels accumulate over time and they give you access to small things like…
Alcohol: what is documented and what is folklore Replied, post #43 · Practice › Interactions · 5 Jun 2026 · 20 likes Anticoagulants: no direct interaction with the compounds in this class. Weight loss and body composition changes might affect the clearance or effect of warfarin if you…
Comparing documentation quality across the directory, tabulated Replied, post #4 · Sourcing › Vendor reports · 31 May 2026 · 7 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #28 · Evidence › Journal club · 27 May 2026 · 7 likes Coming back to post #26, because the follow-up matters more than the original answer. SELECT (N Engl J Med 2023): Semaglutide cardiovascular outcomes without diabetes.…